Co-targeting of the VEGF and FGF pathways led to the restoration of sensitivity to anti-VEGF therapy in bevacizumab-resistant tumors, demonstrating that the upregulation of FGF/FGFR autocrine signaling plays a crucial role in circumventing VEGF inhibition in bevacizumab-resistant tumor cells [30]. The gene discussed is VEGFA; the disease is neoplasm.